What is the difference between Ozempic and Victoza for type 2 diabetes and weight management in Europe?

Ozempic vs Victoza explained: semaglutide vs liraglutide, dosing, effectiveness, side effects, and prescribing criteria.

In this episode, we compare two GLP-1 receptor agonists — Ozempic (semaglutide) and Victoza (liraglutide) — and clarify how they are medically assessed during an online consultation in the EU.

You’ll learn:

• How GLP-1 receptor agonists work to regulate blood glucose and appetite

• Key differences in dosing (weekly vs daily injection)

• Approved indications for type 2 diabetes and weight-related treatment

• Common side effects, including nausea and gastrointestinal symptoms

• Cardiovascular considerations and risk assessment

• Who may meet prescribing criteria based on BMI, HbA1c, and medical history

• Situations where a prescription request may be declined or require specialist input

We explain how doctors review blood test results, current medications, contraindications (such as certain endocrine conditions), and overall metabolic risk before treatment can be considered. Not all patients are suitable for GLP-1 therapy, and ongoing monitoring is essential.

This episode reflects the clinical standards used by Mobi Doctor, where each request is reviewed by a registered physician according to EU prescribing guidelines.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/ozempic-vs-victoza